卡培他滨维持化疗在晚期或术后复发转移胃癌患者中的效果观察

Effect of capecitabine maintenance chemotherapy in patients with advanced or postoperative recurrent and metastatic gastric cancer

目的观察卡培他滨维持化疗在晚期或术后复发转移胃癌患者中的临床效果。方法选取行全身化疗的70例晚期胃癌患者,按照随机抽签1∶1分为研究组和对照组,每组35例。对照组患者接受常规支持治疗,研究组患者接受卡培他滨维持化疗,比较两组患者的临床疗效。结果研究组患者的中位总生存期长于对照组,差异有统计学意义(P﹤0.05)。两组患者1年生存率比较,差异无统计学意义(P﹥0.05);研究组患者2年生存率高于对照组,差异有统计学意义(P﹤0.05)。研究组患者的不良反应总发生率低于对照组,差异有统计学意义(P﹤0.05)。研究组患者各受累器官病灶对于维持化疗反应效果最好的为肝转移病灶,疾病控制率为91.67%(11/12),反应效果最差的为肺转移病灶,疾病控制率为50.00%(2/4)。结论对于接受全身化疗6个周期后病情无进展的晚期或术后复发转移胃癌患者,采取卡培他滨维持化疗可提高患者的2年生存率,取得明显治疗效果的同时安全性较高。

Objective To observe the clinical effect of capecitabine maintenance chemotherapy in patients with advanced or postoperative recurrent and metastatic gastric cancer.Method A total of 70 patients with advanced gastric cancer after systemic chemotherapy were selected.The patients were divided into study group and control group,according to 1∶1 random drawing,35 cases in each group.The patients in the control group were treated with conventional support,while the patients in the study group accepted chemotherapy with capecitabine.The clinical treatment result of the two groups were analyzed.Result The median overall survival in the study group was significantly longer than that in the control group,the difference was statistically significant(P<0.05).There was no significant difference in 1-year survival rate between the two groups(P>0.05).The 2-year survival rate in the study group was significantly higher than that in the control group,the difference was statistically significant(P<0.05).The incidence of clinical adverse reactions in the study group was significantly lower than that in the control group,the difference was statistically significant(P<0.05).In the study group,liver metastases were the most effective organs for maintaining chemotherapy response,the disease control rate was 91.67%(11/12),while lung metastases were the worst,the disease control rate was 50.00%(2/4).Conclusion For the advanced or postoperative metastatic gastric cancer patients without progression after six cycles of systemic chemotherapy,maintain chemotherapy with capecitabine can improve the 2-year survival rate of patients,with obvious therapeutic effect and high safety.